Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2017 08:00 ET | Source: Ovid Therapeutics

Ovid Therapeutics to Present Preclinical Data on TAK-935/OV935 at the Antiepileptic Drug and Device Trials XIV Conference

NEW YORK, May 12, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc., (NASDAQ:OVID) a biopharmaceutical company committed to developing medicines for patients with rare neurological diseases, today...
May 04, 2017 18:20 ET | Source: Ovid Therapeutics

Ovid Therapeutics Announces Pricing of Initial Public Offering

NEW YORK, May 04, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc., a biopharmaceutical company, announced today that it has priced its initial public offering of 5,000,000 shares of its common stock...
April 10, 2017 07:00 ET | Source: Ovid Therapeutics

Ovid Therapeutics Announces Initiation of Phase 1 Clinical Trial of OV101 for Adolescents with Angelman Syndrome or Fragile X Syndrome

NEW YORK, April 10, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics, Inc., a privately held biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
February 09, 2017 08:05 ET | Source: Ovid Therapeutics; NeuroPointDX

Ovid Therapeutics and NeuroPointDX Announce Collaboration to Identify Biomarkers for Angelman Syndrome

NEW YORK and MADISON, Wis., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics, a privately held biopharmaceutical company committed to developing medicines that transform the lives of people with...
February 09, 2017 08:00 ET | Source: Ovid Therapeutics

Ovid Therapeutics Announces First Patient Randomized in the Phase 2 STARS Clinical Trial in Adults with Angelman Syndrome

NEW YORK, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics, a privately held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...
January 19, 2017 08:00 ET | Source: Ovid Therapeutics

Ovid Therapeutics Names Jacqueline A. French, M.D. to Scientific Advisory Board

NEW YORK, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics, a privately held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...
November 29, 2016 16:05 ET | Source: Ovid Therapeutics

Ovid Therapeutics to Participate in Two Upcoming Investor Conferences

NEW YORK, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Ovid Therapeutics, a privately-held biopharmaceutical company committed to developing medicines that transform the lives of people with rare...